Peptide Nucleic Acid as Therapeutic Agent


With a repeating N-(2-aminoethyl)-glycine peptide backbone coupled to purine and pyrimidine nucleobases via a linker, PNA are synthetic analogues of DNA. PNA-based technology has received a lot of interest as a viable method for gene modification due to the unique qualities of PNA, including resistance to enzymatic digestion, increased bio stability, and excellent hybridization affinity toward DNA and RNA. However, inadequate intracellular absorption presents a significant obstacle to the use of PNA. To improve PNA delivery and ensure that it reaches the appropriate spot, some solutions have been devised


    Related Conference of Peptide Nucleic Acid as Therapeutic Agent

    June 13-14, 2024

    30th Asia Pacific Biotechnology Congress

    Dubai, UAE
    July 11-12, 2024

    6th International Conference on Biochemistry

    Paris, France
    September 25-26, 2024

    20th World Congress on Structural Biology

    Paris, France
    October 03-04, 2024

    15th International Conference on Biofuels and Bioenergy

    Singapore City, Singapore
    December 12-13, 2024

    15th World Congress on Cell & Tissue Science

    Rome, Italy

    Peptide Nucleic Acid as Therapeutic Agent Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in